EP Patent

EP3884947A1 — Increasing drug bioavailability in naltrexone therapy

Assigned to Nalpropion Pharmaceuticals LLC · Expires 2021-09-29 · 5y expired

What this patent protects

Disclosed are compositions, uses, methods and kits for increasing drug bioavailability in a naltrexone therapy.

USPTO Abstract

Disclosed are compositions, uses, methods and kits for increasing drug bioavailability in a naltrexone therapy.

Drugs covered by this patent

chembl-chembl2103744 (MORPHINE SULFATE)

Patent Metadata

Patent number: EP3884947A1
Jurisdiction: EP
Classification: —
Expires: 2021-09-29
Drug substance claim: No
Drug product claim: No
Assignee: Nalpropion Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.